Patients, caregivers, and patient advocates: Join the CTTI Patient Summit on April 28 (1:00–3:00 p.m. EDT) to share perspectives on privacy boundaries, participant data access, and AI in clinical trials. 🔗 Register now: duke.zoom.us/meeting/regi...

What should we measure to advance clinical trials? Ed Ramos, former CTTI Executive Committee member, expounds on how CTTI is measuring data reuse and why it matters in reducing participant burden. Watch the video interview now: bit.ly/MTTMetricsFr....

TOMORROW: Join #FDA & #CTTI for a free hybrid workshop to discuss real-world #AI applications & future opportunities in drug and biological product development. Register now: bit.ly/3JuOhZQ

Just a few days left to register for #FDA & #CTTI’s 10/7 hybrid public workshop. Join us to explore innovative, responsible & impactful uses of #AI in drug & biological product development. bit.ly/3JuOhZQ

Next week at #FierceBiotech Week 2025, CTTI’s Lindsay Kehoe will share bold strategies to overcome barriers in clinical research and chart a path toward a more inclusive, efficient, and patient-centered trials ecosystem. 📅 Oct 7 | 9:00 AM | Boston

Final days to register: On 10/7, #FDA & #CTTI will host a hybrid public workshop on how real-world AI use is advancing transparency, quality, safety, and efficacy in product development. bit.ly/3JuOhZQ

Explore cross-disciplinary collaborations & practical steps for using #AI responsibly in medical product development. Join #FDA & #CTTI’s hybrid workshop on 10/7: bit.ly/3JuOhZQ

Join #FDA & #CTTI on 10/7 for a free hybrid workshop exploring how #AI is reshaping drug & biological development. Hear from experts on real-world breakthroughs, data challenges, and what’s next. Register now: bit.ly/3JuOhZQ

Join #FDA & #CTTI on 10/7 for a free hybrid workshop exploring how #AI is reshaping drug & biological development. Hear from experts on real-world breakthroughs, data challenges, and what’s next. Register now: bit.ly/3JuOhZQ

FDA & #CTTI will host a hybrid public workshop on 10/7 to explore the evolving role of #AI in drug & biological product development. Registration is now open: bit.ly/3JuOhZQ

🎥 Why Now, Why Us: Answering the Call to Transform #ClinicalTrials What inspired leaders from across the research ecosystem to attend the #StateOfClinicalTrials? Hear their “why” in this powerful new video from #CTTI. ▶️ Watch now: bit.ly/3HlK1uU

Today #CTTI honors the life of Phil Green, who turned his #ALS diagnosis into a mission to improve #clinicaltrials for all. His leadership, empathy & work with CTTI helped drive more patient-centered, accessible research. His legacy lives on. 🧡 bit.ly/green-phil

How can disease progression modeling support better trial design and decision making? Watch #CTTI’s webinar and explore the recommendations and considerations framework for practical guidance. #DPM bit.ly/460j361

The recording of #CTTI’s webinar on disease progression modeling is now available. Hear expert insights and explore the recommendations & considerations framework to guide thoughtful use of #DPM in clinical development. bit.ly/460j361

Free webinar today @ noon EDT! #CTTI is launching new recs on disease progression modeling (DPM) with keynote speaker Cynthia J. Musante from Pfizer. Learn how DPM can support smarter, more efficient decision making. bit.ly/4nDIAZ4

Flexibility ≠ lower data quality. At #DIA2025, #CTTI led a panel unpacking how #decentralized, patient-centric #clinicaltrials can enhance data integrity — when guided by Quality by Design. More from the conversation: bit.ly/44E39vS

TMRW: Join #CTTI @ noon EDT for a free webinar unveiling new recs on when & how to use disease progression modeling (DPM) in medical product development. bit.ly/3ZoQFGy

🎬 Missed the inaugural State of Clinical Trials meeting? Watch the highlight video to see how 150 leaders are shaping the future of research—together. From patient-centricity to policy shifts, the momentum is real. bit.ly/SOCThighlights

#CTTI’s Watchtower project is developing tools to assess and enhance U.S. #clinicaltrial site capacity—supporting a faster, more unified research response when the next public health emergency strikes. Learn more: bit.ly/44kvet1

From expert meetings to reviewing infrastructure mapping projects, #CTTI’s Watchtower project is gathering the data needed to improve trial site readiness nationwide. Learn how: bit.ly/44kvet1

How do we define trustworthy pharma in 2025? Tomorrow #CTTI’s Morgan Hanger will moderate a small group at the 2025 Ethics & Pharma Roundtable—driving bold ideas on metrics for transparency, trust & patient-first R&D. Don’t miss it!

#CTTI’s Watchtower project is creating a framework to evaluate U.S. #clinicaltrial site readiness— helping to support faster, more coordinated research during future public health emergencies. Learn more: bit.ly/44kvet1

🚨 Join us on 6/24 at the 2025 Roundtable on Ethics, Trust + Patient Centricity in Pharma, hosted by Bioethics International, EY, Yale, & Scientific American! #CTTI's Morgan Hanger speaks on transparency & ethics in #clinicaltrials.

#CTTI’s Watchtower project is assessing #clinicaltrial site readiness in the U.S. to better respond to public health emergencies. Learn how we’re working to rapidly expand research capacity in times of urgent need: bit.ly/44kvet1

#Decentralized #clinicaltrials. Embedded research. Adjusted settings. What do they really mean for data quality? Find out tomorrow at #DIA2025 with #CTTI’s Lindsay Kehoe + experts from FDA, NIH & Florence Healthcare.

Still hitting roadblocks with #QbD and Risk-Based Monitoring? Hear fresh case studies and solutions from CTTI’s Morgan Hanger & experts at #DIA2025 this Wednesday!

Can flexible trials still deliver high-quality data? 🤔 Join us at #DIA2025 on June 18 for, “Do Flexible Trial Approaches Impede Data Quality?” #CTTI’s Lindsay Kehoe leads the convo with @US_FDA, @NIH & @FlorenceHCare. Let’s bust some myths. 💥

Heading to #DIA2025? Join #CTTI’s Morgan Hanger on 6/18 for “Building Upon Quality by Design and Risk-Based Monitoring Implementation Momentum.” New case studies. Real solutions. Practical tools to drive adoption + impact. #clinicaltrials #QbD

Today is the last day to complete the survey for #CTTI’s workshop on #AI in Drug and Biological Product Development. Your input will help shape this year’s agenda: bit.ly/4jCWiIu

DYK that disease progression modeling (DPM) can improve trial efficiency, clarify uncertainty & support precision medicine? Join #CTTI on 7/8 @ noon EDT for a free webinar launching new recs on using DPM in medical product development. bit.ly/3ZoQFGy

There’s still time to share your input for #CTTI’s workshop on #AI in Drug and Biological Product Development. Take the short survey to help guide the discussion: bit.ly/4jCWiIu

150+ leaders. 1 big goal: transform #clinicaltrials. #CTTI’s inaugural #StateOfClinicalTrials meeting tackled the toughest barriers to change—and sparked bold, actionable ideas. 🔗 Dive into the recap: Inside the State of Clinical Trials bit.ly/SOCT

#CTTI is currently planning a future hybrid public workshop on #AI in Drug and Biological Product Development. Help shape the agenda by completing a brief survey: bit.ly/4jCWiIu

Today #CTTI celebrates #ClinicalTrialsDay by recognizing participants, researchers & healthcare heroes advancing medical progress every day. We're proud to work toward faster, more inclusive & patient-centered trials. Let’s keep transforming research—together. #CTD2025 #TT2030

In 2023, over 7,600 U.S. interventional trials were launched—but most remain small, regardless of sponsor. New #SCT2025 research—featuring contributions from #CTTI’s Sara Bristol Calvert—breaks down trial size, focus, and funder differences. Don’t miss it tomorrow!

How do funders shape #clinicalresearch? #CTTI’s Sara Bristol Calvert contributed to new analysis revealing that most U.S. trials are small – and funder type drives the use of behavioral vs drug interventions. Check it out at #SCT2025!

Heading to #SCT2025? Don’t miss new research on U.S. #clinicaltrials launched in 2023, revealing how trial size and focus vary by funding source. #CTTI’s Sara Bristol Calvert contributed to this important work. @sarabc35.bsky.social